{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"16"}]}],"title":"Infusion related reaction Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}],"title":"Infusion related reaction Cycle 2 or higher"},{"categories":[{"measurements":[{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"55"}]}],"title":"No infusion related reaction"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"71"}],"units":"Participants"}],"description":"Incidence of all grades of infusion-related reactions","groups":[{"description":"Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG000","title":"Margetuximab Plus Chemotherapy"},{"description":"Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens","id":"OG001","title":"Trastuzumab Plus Chemotherapy"},{"description":"Margetuximab administered as a 120 minute first infusion in Cycle 1 followed by 60 minute infusion in Cycle 2.","id":"OG002","title":"Margetuximab Stage A1"},{"description":"Margetuximab administered as a 120 minute first infusion in Cycle 1 followed by 30 minute infusion in Cycle 2.","id":"OG003","title":"Margetuximab Stage A2"},{"description":"Margetuximab administered as a 120 minute first infusion in Cycle 1 followed by 30 minute infusion in Cycle 2.","id":"OG004","title":"Margetuximab Stage B"}],"paramType":"NUMBER","populationDescription":"Only patients in the infusion substudy were evaluated for this outcome measure","reportingStatus":"POSTED","timeFrame":"Throughout the study, average duration 6 months","title":"Infusion Rate Sub-study All Safety","type":"SECONDARY","unitOfMeasure":"participants"}